ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,111.23
      1.24%
      US Tech 100
      17,271.20
      1.73%
      Dow Jones
      38,294.27
      0.55%
      Brent Oil
      88.135
      -0.02%
      Bitcoin
      63,880.03
      -0.93%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started

        GILD

        DMG Mori (GILD)

        		Date:
        Sort by:
         Showing the most relevant articles for your search:NASDAQ:GILD
        DateTimeSourceHeadlineSymbolCompany
        04/26/20248:00AMBusiness WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIVNASDAQ:GILDGilead Sciences Inc
        04/26/20247:47AMIH Market NewsExxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in EarningsNASDAQ:GILDGilead Sciences Inc
        04/25/20244:02PMBusiness WireGilead Sciences Announces First Quarter 2024 Financial ResultsNASDAQ:GILDGilead Sciences Inc
        04/25/20247:53AMIH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:GILDGilead Sciences Inc
        04/08/20244:05PMBusiness WireGilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:GILDGilead Sciences Inc
        03/28/20248:30AMBusiness WireFDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixNASDAQ:GILDGilead Sciences Inc
        03/28/20247:00AMBusiness WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
        03/28/20247:00AMGlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
        03/22/20249:18AMBusiness WireGilead Sciences Announces Completion of Acquisition of CymaBayNASDAQ:GILDGilead Sciences Inc
        03/18/20247:29PMBusiness WireCenter for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink GrantNASDAQ:GILDGilead Sciences Inc
        03/11/20248:34AMEdgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:GILDGilead Sciences Inc
        03/11/20248:24AMBusiness WireGilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender OfferNASDAQ:GILDGilead Sciences Inc
        03/06/20244:30PMBusiness WireBiktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and ComorbiditiesNASDAQ:GILDGilead Sciences Inc
        03/06/202410:25AMBusiness WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NASDAQ:GILDGilead Sciences Inc
        03/06/20248:00AMBusiness WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:GILDGilead Sciences Inc
        03/05/20244:35PMBusiness WireNew Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19NASDAQ:GILDGilead Sciences Inc
        03/05/20244:30PMBusiness WireGilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public HealthNASDAQ:GILDGilead Sciences Inc
        02/29/20246:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
        02/29/20244:49PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GILDGilead Sciences Inc
        02/28/20244:38PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GILDGilead Sciences Inc
        02/27/202410:00AMBusiness WireGilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.NASDAQ:GILDGilead Sciences Inc
        02/26/20244:05PMBusiness WireU.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing ResistanceNASDAQ:GILDGilead Sciences Inc
        02/26/20248:30AMBusiness WireGilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024NASDAQ:GILDGilead Sciences Inc
        02/23/20246:09AMEdgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:GILDGilead Sciences Inc
        02/20/20244:31PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GILDGilead Sciences Inc
        02/20/20244:05PMBusiness WireGilead Sciences to Present at Upcoming Investor ConferencesNASDAQ:GILDGilead Sciences Inc
        02/14/20245:08PMEdgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:GILDGilead Sciences Inc
        02/13/20245:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
        02/13/20244:54PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GILDGilead Sciences Inc
        02/13/20244:51PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GILDGilead Sciences Inc
         Showing the most relevant articles for your search:NASDAQ:GILD